Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Royal London Asset Management Ltd.

Royal London Asset Management Ltd. boosted its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 10.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 177,695 shares of the biopharmaceutical company’s stock after buying an additional 17,511 shares during the quarter. Royal London Asset Management Ltd.’s holdings in Royalty Pharma were worth $4,533,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Koss Olinger Consulting LLC purchased a new stake in shares of Royalty Pharma during the fourth quarter worth $269,000. Xponance Inc. grew its stake in Royalty Pharma by 16.2% during the 4th quarter. Xponance Inc. now owns 38,696 shares of the biopharmaceutical company’s stock worth $987,000 after purchasing an additional 5,402 shares in the last quarter. Thrivent Financial for Lutherans increased its holdings in Royalty Pharma by 38.7% during the 4th quarter. Thrivent Financial for Lutherans now owns 475,825 shares of the biopharmaceutical company’s stock worth $12,139,000 after purchasing an additional 132,675 shares during the period. Horizon Kinetics Asset Management LLC raised its position in Royalty Pharma by 39.5% in the 4th quarter. Horizon Kinetics Asset Management LLC now owns 319,176 shares of the biopharmaceutical company’s stock valued at $8,142,000 after purchasing an additional 90,380 shares in the last quarter. Finally, Corient Private Wealth LLC boosted its stake in shares of Royalty Pharma by 86.0% in the 4th quarter. Corient Private Wealth LLC now owns 46,249 shares of the biopharmaceutical company’s stock valued at $1,180,000 after buying an additional 21,383 shares during the period. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Stock Up 0.6 %

Shares of NASDAQ RPRX opened at $33.70 on Monday. The business has a 50-day moving average of $32.25 and a two-hundred day moving average of $28.71. The company has a market capitalization of $19.43 billion, a price-to-earnings ratio of 23.24, a price-to-earnings-growth ratio of 2.31 and a beta of 0.47. Royalty Pharma plc has a 1 year low of $24.05 and a 1 year high of $34.20. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. On average, analysts forecast that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, March 10th. Stockholders of record on Friday, February 21st were issued a $0.22 dividend. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Friday, February 21st. This represents a $0.88 annualized dividend and a dividend yield of 2.61%. Royalty Pharma’s dividend payout ratio is presently 60.69%.

Analyst Ratings Changes

Separately, TD Cowen raised Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $41.60.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.